What does a clear ma­jor­i­ty of the bio­phar­ma in­dus­try think of the FDA ap­proval of ad­u­canum­ab? 'Hor­ri­fy­ing' 'Dan­ger­ous' 'Con­fus­ing' 'Dis­as­ter'

Over the years, we’ve be­come used to see­ing a con­sen­sus emerge ear­ly in our in­dus­try polls at End­points News. And when we took the pulse of drug hunters on the heels of a con­tro­ver­sial FDA ap­proval for ad­u­canum­ab this week, it be­came im­me­di­ate­ly ap­par­ent that the vast ma­jor­i­ty of our read­ers — heav­i­ly con­cen­trat­ed among bio­phar­ma staffers and ex­ecs — were in­censed by what they had just wit­nessed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER